Parpos Nurse
🛑 👉🏻👉🏻👉🏻 INFORMATION AVAILABLE CLICK HERE👈🏻👈🏻👈🏻
Newton-Wellesley Physicians, Cardiology
2014 Washington Street, Elfers Cardiovascular Center 2 West
Board Certification, Echocardiography, 2010
Board Certification, Cardiovascular Disease, 2009
Board Certification, Cardiovascular Computed Tomography, 2009
Board Certification, Nuclear Cardiology, 2008
Board Certification, Internal Medicine, 2005
Note: This provider may accept more insurance plans than shown. Please call the practice to find out if your plan is accepted.
NOTES:
- "Affiliation" is the local physician organization to which the doctor belongs.
- A primary care provider (or PCP) is a doctor or in some cases, a nurse practitioner or physician assistant, who sees patients for everyday medical issues, such as colds and annual wellness visits. PCPs often are your first point of contact for your general health concerns.
- Providers who are "accepting new patients" are able to book new patient appointments within 90 days. "Accepting new patients" is subject to change. Please confirm when setting up your appointment.
- Primary Care providers who have "near-term availability" can book new patient appointments within 30 days. "Near-term availability" is subject to change. Please confirm when setting up your appointment.
- "Concierge Medicine" is a unique offering in which providers care for a limited population of patients. Patients can opt into this "direct primary care" model with an annual membership fee.
- Providers may accept more insurance plans than shown. Please confirm when setting up your appointment.
© 2020 Mass General Brigham Incorporated. All Rights Reserved.
We use cookies and other tools to enhance your experience on our website and to analyze our web traffic. For more information about these cookies and the data collected, please refer to our Privacy Policy.
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education
Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out Cancel
This activity is intended for nurses who manage patients with ovarian cancer undergoing treatment with PARP inhibitors.
The goal of this activity is to improve knowledge and competence of management of patients with ovarian cancer undergoing treatment with PARP inhibitors.
Upon completion of this activity, participants will:
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Professor, Cedar-Sinai Medical Center, Los Angeles, California
Disclosure: Beth Y. Karlan, MD, has disclosed no relevant financial relationships.
Dr Karlan does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.
Dr Karlan does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.
Clinical Nurse Specialist, Cedars-Sinai Medical Center, Los Angeles, California
Disclosure: Paula J. Anastasia, RN, MN, AOCN, has disclosed the following relevant financial relationships:
Served as a speaker or a member of a speakers bureau for: Clovis Oncology; Genentech, Inc.
Ms Anastasia does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.
Ms Anastasia does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.
Nurse Practitioner, Division of Gynecology Oncology, Arizona Oncology, Phoenix, Arizona
Disclosure: Kimberly Halla, MSN, FNP-C, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Heron Therapeutics, Inc.
Served as a speaker or a member of a speakers bureau for: Clovis Oncology
Ms Halla does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.
Ms Halla does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.
Disclosure: Sara Fagerlie, PhD, CHCP, has disclosed no relevant financial relationships.
Disclosure: Lori K. Pender, PharmD, MPH, BCOP, has disclosed no relevant financial relationships.
Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.
Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0.50 contact hours are in the area of pharmacology.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact CME@medscape.net
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
Authors: Beth Y. Karlan, MD; Paula J. Anastasia, RN, MN, AOCN; Kimberly Halla, MSN, FNP-CFaculty and Disclosures
Valid for credit through: 3/28/2019
The goal of this activity is to improve knowledge and competence in the management of patients with ovarian cancer undergoing treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor.
Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.
Kelly, a 65-year-old patient with recurrent breast cancer gene 1 and 2 (BRCA1/BRCA2)-negative ovarian cancer has a partial response to platinum-based chemotherapy
Which of the following statements regarding maintenance therapy with a poly (ADP-ribose) polymerase (PARP) inhibitor is true?
Because Kelly is BRCA1/BRCA2 negative, she would not be eligible for maintenance therapy with a PARP inhibitor
Because Kelly did not have a complete response to platinum-based chemotherapy, she would not be eligible for maintenance therapy with a PARP inhibitor
Because Kelly's ovarian cancer is not resistant to platinum-based therapy, she would not be eligible for maintenance therapy with a PARP inhibitor
Kelly is a candidate for maintenance therapy with a PARP inhibitor
Kelly chooses to start on niraparib maintenance therapy. Kelly has a platelet count of 143,000/mm3 and weighs 145 lb (66 kg).
On what dose of niraparib should Kelly be started?
Which of the following treatment-related adverse events commonly occur with all 3 PARP inhibitors (olaparib, niraparib, and rucaparib)?
How confident are you in your ability to educate patients about PARP inhibitor-related adverse events? (Select ranking from 1 [Not confident] to 5 [Very confident])
Please indicate how relevant this activity is to your practice. On average, how many patients with ovarian, fallopian tube, or primary peritoneal cancer do you see in a month?
The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.
The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Medscape Education © 2018 Medscape, LLC
All material on this website is protected by copyright, Copyright © 1994-2021 by WebMD LLC. This website also contains material copyrighted by 3rd parties.
New Sex Download
New Porn Box Truck
Latin Girls
Latin Grammy 2021
Handjob Two Dicks
Parpos: The unsung heroes of education - News - The ...
Parpos: Confessions of a single woman - News - The ...
Dr. Stefanos Parpos, MD - Newton, MA - Cardiology ...
The Nurse View: Clinical Considerations in the use of PARP …
Our Cardiovascular Team | Newton-Wellesley Hospital
Dr. Stefanos Parpos - Newton MA, Cardiovascular Disease ...
Dr. Stefanos Parpos, MD | Newton, MA | Healthgrades
62,649 Purpose Photos - Free & Royalty-Free Stock Photos ...
"Para-nursing" - General Nursing - allnurses®
Dr. Stefanos Parpos Jr. - Waltham MA, Cardiovascular ...
Parpos Nurse
